Printer Friendly
The Free Library
14,529,525 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare Tailwinds Conference.


WALTHAM, Mass. -- - Webcast of presentation available Friday, September 9, 2005 at 9:10 AM ET -

Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Thomas Weisel Healthcare Tailwinds Conference on September 9, 2005 in Boston. The Company's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE Fac´tive

a. 1. Making; having power to make.
(R) (gemifloxacin mesylate gemifloxacin mesylate

Factive

Pharmacologic class: Quinolone

Therapeutic class: Broad-spectrum anti-infective

Pregnancy risk category C

Action

) tablets, the Company's lead product. The presentation will begin at 9:10 AM ET on Friday and will be webcast through the Company's website at www.oscient.com. An archive of the webcast will also be available for 30 days.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. In addition to the oral tablet form, Oscient Pharmaceuticals is developing an investigational FACTIVE intravenous formulation for use in hospitalized patients. The Company is also promoting Auxilium Pharmaceuticals' TESTIM (R) 1% testosterone gel to primary care physicians in the U.S. Oscient has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium clostridium

Any of the rod-shaped, usually gram-positive bacteria (see gram stain) that make up the genus Clostridium. They are found in soil, water, and the intestinal tracts of humans and other animals. Some species grow only in the complete absence of oxygen.
 difficile-associated diarrhea (CDAD CDAD Clostridium Difficile-Associated Diarrhea
CDAD Component Data Administrator
).
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 2, 2005
Words:219
Previous Article:Valero Energy Corporation Announces Final Results of Elections for Merger Consideration.
Next Article:Reichhold Announces Price Increase for Composites Products in North America; $ 0.10 per Pound Effective October 1, 2005; No Supply Interruption...



Related Articles
Millipore's Chairman at Thomas Weisel Healthcare Tailwinds 2002 Conference on April 29th.
Centene Corporation to Present at the Thomas Weisel Partners Healthcare Tailwinds 2003 Conference.
Orphan Medical to Present at Thomas Weisel Healthcare Tailwinds 2003 Conference.
Millipore's Chairman at Thomas Weisel Healthcare Conference on September 3.
Corixa to Present at Biocentury Newsmakers and Thomas Weisel Partners Healthcare Conferences.
CORRECTING and REPLACING EXACT Sciences to Webcast Presentation at Thomas Weisel Partners' Healthcare Tailwinds 2003 Conference.
Charles River Laboratories to Present at September Conferences.
Charles River Laboratories to Present at September Conferences.
Mentor to Present at Thomas Weisel Partners Healthcare Tailwinds 2005 Conference; Thursday, September 8, 2005 at 3:50 PM, EDT.
Gilead Sciences to Present at Two Upcoming Investor Conferences.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles